graft-versus-host disease
GVHD

GVHD and antimicrobial prophylaxis were the same for all patients.

GVHD does not occur when an identical twin is the donor.

GVHD is treated with medicine that lowers the activity of your immune system.

However, this was at the expense of increased rate of GVHD.

The increase in acute GVHD in this group, however, was unexpected.

The GVHD had caused an extreme itch and burn over his whole body.

The mechanisms by which chronic GVHD develops are as yet ill-defined.

If it happens within 3 months, it is called acute GVHD.

After chronic GVHD develops, it may take as long as 3 years to go away.

Pre-existing hepatic disease, including infection, and GVHD may increase the risk.

GVHD affects the skin, gastrointestinal tract, and liver.

It is used as first-line treatment for both acute and chronic GVHD of the skin.

GVHD can also occur after a blood transfusion if the blood products used have not been irradiated.

Liver GVHD is measured by the bilirubin level in acute patients.

Patients with grade IV GVHD usually have a poor prognosis.

The symptoms are very similar to graft-versus-host disease (GVHD).

Treatment of oral GVHD may include the following:

Transfusion-associated GVHD is rare in modern medicine.

Therefore, these T cells are auto-reactive and cause the GVHD phenotype.

Corticosteroids and graft-versus-host disease (GVHD) may further increase risk.

It is also the first therapy approved by Canada for acute graft-vs-host disease (GvHD).

Patients who undergo donor bone marrow transplantation may develop graft-versus-host disease (GVHD).

To manage diarrhea caused by graft-versus-host disease (GVHD), the doctor may recommend a special 5-phase diet.

Oral GVHD has also been linked with oral precancerous and malignant lesions.

Chronic oral GVHD changes can be recognized as early as day 70 posttransplant.